Search

Displaying results 6641 - 6650 of 7067 in total
  1. Drug

    CHF 4227

    go.drugbank.com/drugs/DB05882
    Experimental

    CHF 4227 is a new selective estrogen receptor modulator (SERM). … The compound has a high receptor affinity and has shown promising efficacy in the prevention of bone loss in animal models of osteoporosis.

  2. Drug

    TAFA-93

    go.drugbank.com/drugs/DB05887
    Experimental

    , the treatment of autoimmune and oncological diseases, and as a component of coated stents for the treatment of coronary artery disease. … TAFA93 is a novel prodrug of the mTOR inhibitor rapamycin which has successfully completed Phase 1 clinical development. mTOR inhibitors are currently used in the prevention of organ rejection in transplantation

  3. Drug

    RI 624

    go.drugbank.com/drugs/DB05892
    Experimental

    RI 624 is a novel humanized monoclonal antibody that blocks nerve growth factor (NGF), a key mediator of acute and chronic pain.

  4. Drug

    CCR5 mAb

    go.drugbank.com/drugs/DB05906
    Experimental

    CCR5 mAb is a fully human monoclonal antibody that specifically recognizes and binds the chemokine receptor CCR5, which is known to be a key facilitator of infection with human immunodeficiency virus (

  5. Drug

    OSI-930

    go.drugbank.com/drugs/DB05913
    Investigational

    OSI-930 is an orally active inhibitor of two clinically validated targets: c-Kit and the vascular endothelial growth factor receptor-2 (VEGFR-2). OSI-930 is designed to target both cancer cell proliferation and blood vessel growth (angio...

  6. Drug

    LS11

    go.drugbank.com/drugs/DB05918
    Investigational

    LS11(talaporfin sodium) is an agent consisting of chlorin e6, derived from chlorophyll, and L-aspartic acid with photosensitizing activity. After intratumoral activation by light emitting diodes, taporfin sodium forms an extended high en...

  7. Drug

    Leronlimab

    go.drugbank.com/drugs/DB05941
    Investigational

    Leronlimab, or PRO-140, is a human monoclonal antibody developed by CytoDyn.[L12684] It was first described in the literature in 2001.

  8. Drug

    MDX-1303

    go.drugbank.com/drugs/DB05945
    Investigational

    MDX-1303 is a fully human antibody against the inhalation anthrax, the most lethal form of illness in humans caused by the Bacillus anthracis bacterium, and targets a protein component of these lethal

  9. Drug

    MN-246

    go.drugbank.com/drugs/DB05981
    Experimental

    MN-246 is a novel ß3-adrenergic receptor agonist developed for the treatment of urinary incontinence by MediciNova Inc.

  10. Drug

    Bardoxolone methyl

    go.drugbank.com/drugs/DB05983
    Investigational